DOI QR코드

DOI QR Code

Differential Distribution of microRNAs in Breast Cancer Grouped by Clinicopathological Subtypes

  • Li, Jian-Yi (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Jia, Shi (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Zhang, Wen-Hai (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Zhang, Yang (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Kang, Ye (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Li, Pi-Song (Department of Breast Surgery, Shengjing Hospital of China Medical University)
  • Published : 2013.05.30

Abstract

Background: microRNAs (miRNAs) that regulate proliferation, invasion and metastasis are considered to be the principal molecular basis of tumor heterogeneity. Breast cancer is not a homogeneous tissue. Thus, it is very important to perform microarray-based miRNA screening of tumors at different sites. Methods: Breast tissue samples from the centers and edges of tumors of 30 patients were classified into 5 clinicopathological subtypes. In each group, 6 specimens were examined by microRNA array. All differential miRNAs were analyzed between the edges and centers of the tumors. Results: Seventeen kinds of miRNAs were heterogeneously distributed in the tumors from different clinicopathological subtypes that included 1 kind of miRNA in Luminal A and Luminal B Her2+ subtypes, 4 kinds in Luminal A and Her2 overexpression subtypes, 6 kinds in Luminal B Ki67+ and Luminal B Her2+ subtypes, 2 kinds between Luminal B Ki67+ and triple-negative breast cancer (TNBC) subtypes, 2 kinds between Luminal B Her2+ and TNBC subtypes, and 2 kinds between Luminal B Ki67+, Luminal B Her2+, and TNBC subtypes. Twenty kinds of miRNAs were homogenously distributed in the tumors from different clinicopathological subtypes that included 6 kinds of miRNAs in Luminal B Ki67+ and Luminal B Her2+ subtypes, 1 kind in Luminal B Ki67+ and Her2 overexpression subtypes, 10 kinds between Luminal B Ki67+ and TNBC subtypes, 2 kinds in Luminal B Her2+ and TNBC subtypes, and 1 kind between Luminal B Ki67+, Luminal B Her2+, and TNBC subtypes. Conclusions: A total of 37 miRNAs were significantly distributed in tumors from the centers to edges, and in all clinicopathological subtypes.

Keywords

microRNA;breast cancer;clinicopathological subtype;heterogeneity

References

  1. Aihara M, Wheeler TM, Ohori M, et al (1994) Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology, 43, 60-6 https://doi.org/10.1016/S0090-4295(94)80264-5
  2. Balsat C, Blacher S, Signolle N, et al (2011). Whole slide quantification of stromal lymphatic vessel distribution and peritumoral lymphatic vessel density in early invasive cervical cancer: a method description. ISRN Obstet Gynecol, 25, 1-7.
  3. Caporali A, Emanueli C (2011). MicroRNA regulation in angiogenesis. Vascul Pharmacol, 55, 79-86. https://doi.org/10.1016/j.vph.2011.06.006
  4. Cheng C, Fu X, Alves P, et al (2009). mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol, 10, R90. https://doi.org/10.1186/gb-2009-10-9-r90
  5. Choudhry H, Catto JW (2011). Epigenetic regulation of microRNA expression in cancer. Methods Mol Biol, 676, 165-84. https://doi.org/10.1007/978-1-60761-863-8_12
  6. Cortes-Sempere M, Ibanez de Caceres I (2011). microRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol, 13, 357-62 https://doi.org/10.1007/s12094-011-0668-z
  7. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
  8. Hughes DP (2009). How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res, 152, 479-96 https://doi.org/10.1007/978-1-4419-0284-9_28
  9. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70 https://doi.org/10.1158/0008-5472.CAN-05-1783
  10. Juan HF, Huang HC (2007). Bioinformatics: microarray data clustering and functional classification. Methods Mol Biol, 382, 405-16. https://doi.org/10.1007/978-1-59745-304-2_25
  11. Kitadai Y, Ellis LM, Takahashi Y, et al (1995). Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin Cancer Res, 1, 1095-102.
  12. Kreiner T, Buck KT (2005). Moving toward whole-genome analysis: a technology perspective. Am J Health Syst Pharm, 62, 296-305.
  13. Krishna MC, Matsumoto S, Yasui H, et al (2012). Electron paramagnetic resonance imaging of tumor $pO_{2}$. Radiat Res, 177, 376-86 https://doi.org/10.1667/RR2622.1
  14. Li JY, Zhang Y, Zhang WH, et al (2012). Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pac J Cancer Prev, 13, 1901-6. https://doi.org/10.7314/APJCP.2012.13.5.1901
  15. Orlando PA, Gatenby RA, Brown JS (2013). Tumor evolution in space: the effects of competition colonization tradeoffs on tumor invasion dynamics. Front Oncol, 3, 45.
  16. Pritchard CC, Cheng HH, Tewari M (2012). MicroRNA profiling: approaches and considerations. Nat Rev Genet, 13, 358-69.
  17. Stransky B, de Souza SJ (2012). Modeling tumor evolutionary dynamics. Front Physiol, 3, 480.
  18. Teixeira MR, Heim S (2011). Cytogenetic analysis of tumor clonality. Adv Cancer Res, 112, 127-49 https://doi.org/10.1016/B978-0-12-387688-1.00005-3
  19. Wilson DF, Cerniglia GJ (1992). Localization of tumors and evaluation of their state of oxygenation by phosphorescence imaging. Cancer Res, 52, 3988-93.

Cited by

  1. Down-regulation of miRNA-452 is Associated with Adriamycin-resistance in Breast Cancer Cells vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5137
  2. MiR-886-5p Inhibition Inhibits Growth and Induces Apoptosis of MCF7 Cells vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1511
  3. miR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis vol.20, pp.46, 2014, https://doi.org/10.3748/wjg.v20.i46.17439
  4. MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice vol.18, pp.1, 2016, https://doi.org/10.1186/s13058-016-0735-z
  5. Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data vol.34, pp.11, 2017, https://doi.org/10.1007/s12032-017-1043-x
  6. MicroRNAs and Triple Negative Breast Cancer vol.14, pp.11, 2013, https://doi.org/10.3390/ijms141122202
  7. Differential microRNA expression in breast cancer with different onset age vol.13, pp.1, 2018, https://doi.org/10.1371/journal.pone.0191195
  8. miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer vol.14, pp.18, 2018, https://doi.org/10.2217/fon-2018-0061